Afuco™ Anti-IGF1R ADCC Therapeutic Antibody (Figitumumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IGF1 Receptor. Figitumumab (previously CP-751871) is a monoclonal antibody targeting the insulin-like growth factor-1 receptor being investigated for the treatment of various types of cancer, for example adrenocortical carcinoma and non-small cell lung cancer (NSCLC).
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-232 |
| Pricing | Inquiry |
| Host | Human |
| Target | IGF1R |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | IF, IP, Neut, FuncS, ELISA |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |